PDSB
PDS Biotechnology Corporation Common Stock
stockNASDAQ
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology's proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.37 | 2026-11-02 | -10.58% | 1.342 |
| 1M | 1.02 | 2026-10-08 | +20.10% | 4.439 |
| 3M | 0.78 | 2026-08-07 | +58.00% | 2.441 |
| 6M | 1.25 | 2026-05-08 | -2.00% | 2.497 |
| 1Y | 0.91 | 2025-11-07 | +34.53% | 2.809 |
| 2Y | 3.29 | 2024-11-08 | -62.77% | — |
| 5Y | 11.44 | 2021-11-08 | -89.29% | 1.998 |
PDS Biotechnology Corporation Common Stock (NASDAQ:PDSB) stock price today is $1.23, and today's volume is 2,946,858. The 30 day average volume is 9.92M. PDSB market cap is $88.78M with 72.47M shares outstanding.